BridgeBio Signs Supply Contract Worth 1.3 Billion KRW
[Asia Economy Reporter Eunmo Koo] Bridge Biotherapeutics announced on the 2nd that it has signed a supply contract worth 1,328,260,000 KRW for BBT-877 clinical phase 2 trial drugs with Boehringer Ingelheim Pharma GmbH & Co. KG in Germany. The contract period is until December 31, 2023.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Iranian Stock Market Reopens After 80 Days Following War
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
